Astellas Receives Approval for a Supplemental New Drug Application for Irribow® Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella - Granisetron - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-05-26 01:47:13 Antiemetics Abdominal pain General practice Syndromes Ketones Irritable bowel syndrome Diarrhea Ramosetron 5-HT3 antagonist Medicine Health Gastroenterology		Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella Add to Reading List Source URL: www.astellas.com Download Document from Source Website File Size: 73,81 KB Share Document on Facebook

	FMS Fact Sheet Syndrome Description FMS is a chronic, body-wide pain disorder coupled with other symptoms, such as severe daytime fatigue, unrefreshed sleep (likely due to a number of sleep anomalies), irritable bowel, c DocID: 1uIMS - View Document
	Understanding Genetic Causes of Irritable Bowel Syndrome Through Learned Models of Stress-Related and Inflammatory Bowel Syndrome Diseases Jean Feng June 5, 2012 Abstract DocID: 1uzyp - View Document
	IRRITABLE BOWEL SYNDROME (IBS) OVERVIEW — Irritable bowel syndrome (IBS) is a chronic condition of the digestive system. Its primary symptoms are abdominal pain and altered bowel habits but these symptoms have no ident DocID: 1rt2s - View Document
	IBS in the Real World Survey SUMMARY FINDINGS AU G U S TInternational Foundation for Functional Gastrointestinal Disorders DocID: 1qE37 - View Document
	AMERICAN COLLEGE OF GASTROENTEROLOGY Pregnancy in Gastrointestinal Disorders DocID: 1qxyG - View Document